$R_{esponse} E_{valuation} In N_{eurofibromatosis} S_{chwannomatosis} \\ INTERNATIONAL COLLABORATION$

- If sharing any data or information from these slides generated by the REiNS International Collaboration, please acknowledge the authors, group chairs, and specific working group.
- If using any information presented with a citation, please reference the primary source.



Assessing established PROs for cNFs: are these scales adequate for clinical trials?

Dominique C. Pichard, MD on behalf of the cNF Working Group September 22, 2019



 $R_{esponse} E_{valuation} I_n N_{eurofibromatosis} S_{chwannomatosis} \\ INTERNATIONAL COLLABORATION$

- cNFs affect more than 99% of adults with NF1
- No malignant potential but have significant negative effects on quality of life
- Current treatment is limited to surgical and destructive methods
- No validated tools to assess improvement on quality of life after treatment of cNFs










Patient-centered cNF research



Lack of data concerning how patients assess morbidity related to cNFs and how they view current and potential cNF treatments



The patient-focused drug development meetings conducted to date have given FDA a deeper appreciation for the expertise that patients and caregivers can bring to the process and the value of incorporating their voice.





A PRO instrument, like physician-based instruments, should be shown to measure the concept it is intended to measure, and the FDA will review the evidence that a particular PRO instrument measures the concept claimed".



FDA Guidance: PRO Measures – Use in medical product development to support labeling claims. 2009⁶

Process



Review the literature for existing PROs that are specific for assessing the skin





- Review of the literature: Skin specific PRO instruments identified
 - Skindex & teen-skindex
 - Dermatology life quality index (DLQI) & CDLQI
 - Adjusted NF QOL (Hilda Crawford)
 - Itch scales
 - Pain scales



Rate PROs

ed Outcomes Rating Acceptance Tool for Endpoints or REINS Committee use only)

Disease-Specific QOL Pain Functional Disability

Dat	e:
pporting its use in neurofibro rmation but needs more work 0=No/poor data/information *Half ratings (.5, 1.5, 2.5) can be used if needed	matosis trials c
Rating Criteria	Rating (0-3):
1. <u>Patient characteristics</u> : Age range (e.g., child, adolescent, adult)	use in NF trials
Normative groups (e.g., general, NF, oncology, other, # subjects)	
2. <u>Used in published studies</u> : Number and types of studies (e.g., descriptive, clinical trials)	
3. <u>Domains assessed/Item content:</u> Number/description (e.g., physical, social, emotional, cognitive)	
4. <u>Scores available</u> : Item response format (e.g., Likert scale, visual analog scale)	
Types of scores (e.g., raw, standardized, domain, total)	

Neu

tosis & Schwar

5. <u>Psychometric Data</u> : Reliability (e.g., internal consistency, test/retest)	
Validity (e.g., construct, discriminative)	
Factor analysis	
6. <u>Feasibility</u> : Cost	
Length (number of items)	
Ease of administration	
Recall period assessed (e.g., 1 week, 24 hours)	
Availability in different languages/International use	
Overall Impression for use in NF Clinical Trials (Pros'Cons): Rectangu	Total (mean):

Level of Acceptance (Committee decision):

Primary outcome measure

Secondary outcome measure

Not acceptable at this time/further information needed (specify) Not acceptable (no further review)

Committee notes/comments/additional information needed/plan:

	HOW OFTEN DURING THE PAST FOUR WEEKS DO THESE STATEMENTS DESCRIBE YOU?	NEVER	RARELY	SOMETIMES	OFTEN	ALL THE TIME
	1. My skin hurts			□₃	□₄	□₅
	2. My skin condition affects how well I sleep			□₃	□₄	□₅
	3. I worry that my skin condition may be serious			□₃		□₅
	4. My skin condition makes it hard to work or do hobbies			< □₃	□₄	□₅
	5. My skin condition affects my social life		- B	□3	□₄	□₅
	6. My skin condition makes me feel depressed			□₃	□₄	□₅
	7. My skin condition burns or stings	્રેષ્ટ્ર		□₃	□₄	□₅
	8. I tend to stay at home because of my skin condition	N .		□₃	□₄	□s
	9. I worry about getting scars from my skin condition			□₃	□₄	□s
	10. My skin itches			□₃		□₅
	11. My skin condition affects how close I can be with those I love .			□₃	□₄	□s
	12. I am ashamed of my skin condition			□₃	□₄	□s
	13. I worry that my skin condition may get worse			□₃	□₄	□₅
	14. I tend to do things by myself because of my skin condition .			□₃	□₄	□₅
	15. I am angry about my skin condition			□₃	□₄	□₅
	18. Water bothers my skin condition (bathing, washing hands) .			□₃	□₄	□₅
	17. My skin condition makes showing affection difficult			□₃	□₄	□s
	18. I worry about side-effects from skin medications / treatments .			□₃	□₄	□₅
a a	19. My skin is irritated			□₃	□₄	□₅
Porte	20. My skin condition affects my interactions with others			□₃	□₄	

se Evalu

is & Sch

10

HOW OFTEN DURING THE PAST 4 WEEK DO THESE STATEMENTS DESCRIBE YOU?	NEVER	RARELY	SOMETIMES
21. I am embarrassed by my skin condition			□₃
22. My skin condition is a problem for the people I love			
23. I am frustrated by my skin condition			
24. My skin is sensitive			□₃
25. My skin condition affects my desire to be with people		<u> </u>	□,
26. I am humiliated by my skin condition		GE2	
27. My skin condition bleeds			\square_3
28. I am annoyed by my skin condition	¢,		
29. My skin condition interferes with my sex life .			
30. My skin condition makes me tired			□₃



S K

Ν

D E X Skindex PRO RATE Overall impression: 2.54/3.0


PROS

- Ages 12-17, ≥18
- Used widely in general derm.
- Qs appropriate for cNFs
- Feasibility

CONS

- No interventional trial data
- Questions not relevant to NF1
- "my skin condition"







GOVERNMENT




Skindex Scores









1.	Over the last week, how itchy , sore , painful or stinging has your skin been?	Very much A lot A little Not at all		
2.	Over the last week, how embarrassed or self conscious have you been because of your skin?	Very much A lot A little Not at all		
3.	Over the last week, how much has your skin interfered with you going shopping or looking after your home or garden ?	Very much A lot A little Not at all	Not relevant	
4.	Over the last week, how much has your skin influenced the clothes you wear?	Very much A lot A little Not at all	Not relevant	
5.	Over the last week, how much has your skin affected any social or leisure activities?	Very much A lot A little Not at all	Not relevant	
6.	Over the last week, how much has your skin made it difficult for you to do any sport ?	Very much A lot A little Not at all	Not relevant	
7.	Over the last week, has your skin prevented you from working or studying ?	Yes No	Not relevant	
	If "No", over the last week how much has your skin been a problem at work or studying ?	A lot A little Not at all		
8.	Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives ?	Very much A lot A little Not at all	Not relevant	
9.	Over the last week, how much has your skin caused any sexual difficulties?	Very much A lot A little Not at all	Notrelevant	
10.	Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy, or by taking up time?	Very much A lot A little		





C D L Q I



(C)DLQI PRO RATE

Overall impression: 2.5/3.0 (2.65/3)

PROS

- Ages 4-16, ≥16
- Used widely in derm. (>1000 pub)
- Qs appropriate for cNFs
- Feasibility

CONS

- No interventional trial data
- Multiple domains in single question
- Raw score, interpretation is not validated





Future directions

- Skindex: modifications to change wording from "my skin" to "my cutaneous neurofibromas"
 - Makes scale more specific to cNFs
 - Helps patients not rate skin AEs of a drug
- DLQI: modifications to the scale is more broad
 - Questions that have multiple domains need to be separated
 - Will require rewriting multiple questions and keeping the questionnaire an appropriate length and understandability



• ? Develop de novo cNF PRO

Acknowledgements

- Pam Wolters
- Dawn Siegel
- Khaled Ezzedine,
- Betty Schorry
- Carolina Barnett Tapia

REiNS PRO and cNF working groups

Ashley Cannon, UAB

